|
|
|
|
| LEADER |
00000cam a2200000 7i4500 |
| 001 |
0000057616 |
| 005 |
20100125093000.0 |
| 008 |
080526s2007 nyu eng |
| 020 |
|
|
|a 0387728988 (alk. paper)
|
| 020 |
|
|
|a 9780387728988 (alk. paper)
|
| 050 |
0 |
0 |
|a R853.C55
|b F87 2007
|
| 060 |
1 |
0 |
|a W 20.5
|b F983e 2007
|
| 090 |
0 |
0 |
|a W 20.5
|b F983e 2007
|
| 100 |
1 |
|
|a Furberg, Bengt ,
|e author
|
| 245 |
1 |
0 |
|a Evaluating clinical research :
|b all that glitters is not gold
|c Bengt D Furbert and Curt D Furberg
|
| 250 |
|
|
|a 2nd ed
|
| 260 |
|
|
|a New York :
|b Springer Verlag ,
|c c2007
|
| 300 |
|
|
|a 161 p. :
|b ill., ports. ;
|c 24 cm.
|
| 504 |
|
|
|a Includes bibliographical references (p 149-158) and index
|
| 505 |
0 |
|
|a 1. What is the purpose of this book? -- 2. Why is benefit-to-harm balance essential to treatment decisions? -- 3. What are the strengths of randomized controlled clinical trials? -- 4. What are the weaknesses of randomized controlled clinical trials? -- 5. Do meta-analyses provide the ultimate truth? -- 6. What are the strengths of observational studies? -- 7. What are the weaknesses of observational studies? -- 8. Were the scientific questions stated in advance? -- 9. Were the treatment groups comparable initially? -- 10. Why is blinding/masking so important? -- 11. How is symptomatic improvement measured? -- 12. Is it really possible to assess quality of life? -- 13. What is the value of biologic markers in drug evaluation? -- 14. How are adverse drug reactions measured? -- 15. How representative are study subjects in clinical trials? -- 16. What happened to the study subjects who disappeared from the analysis? -- 17. How reliable are active-control trials? -- 18. How informative are composite outcomes? -- 19. Do changes in biologic markers predict clinical benefit? -- 20. How trustworthy are the authors? -- 21. Does publication in a reputable scientific journal guarantee quality? -- 22. Is it necessary to be a biostatistician to interpret scientific data? -- 23. Are all drugs of a class interchangeable? -- 24. How much confidence can be placed on economic analysis? -- 25. How should I handle the massive flow of information? -- 26. How well is research translated into clinical care?
|
| 650 |
|
0 |
|a Clinical medicine
|x Research
|
| 650 |
|
0 |
|a Clinical trials
|
| 650 |
|
0 |
|a Medicine
|x Research
|
| 650 |
1 |
2 |
|a Biomedical Research
|x methods
|
| 650 |
2 |
2 |
|a Clinical Trials as Topic
|
| 650 |
2 |
2 |
|a Drug Evaluation
|
| 650 |
2 |
2 |
|a Research Design
|
| 700 |
1 |
|
|a Furberg, Curt ,
|e author
|
| 856 |
4 |
1 |
|3 Table of contents only
|u http://www.loc.gov/catdir/enhancements/fy0826/2007930204-t.html
|
| 856 |
4 |
2 |
|3 Publisher description
|u http://www.loc.gov/catdir/enhancements/fy0826/2007930204-d.html
|
| 999 |
|
|
|a 1000118513
|b Book
|c OPEN SHELF (30 DAYS)
|e Medical Campus
|